Separately, Zacks Investment Research upgraded Fennec Pharmaceuticals from a hold rating to a buy rating and set a $5.75 price objective on the stock in a research note on Friday, November 15th.
Shares of NASDAQ FENC opened at $6.24 on Friday. The business’s 50 day moving average is $5.23 and its 200-day moving average is $4.49. Fennec Pharmaceuticals has a 1-year low of $3.26 and a 1-year high of $7.65. The firm has a market cap of $124.59 million, a P/E ratio of -12.48 and a beta of 0.21.
Fennec Pharmaceuticals (NASDAQ:FENC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.11. On average, research analysts predict that Fennec Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Wedbush Securities Inc. bought a new position in Fennec Pharmaceuticals during the 3rd quarter worth $57,000. Atria Investments LLC bought a new position in Fennec Pharmaceuticals during the 2nd quarter worth $215,000. Hartford Financial Management Inc. increased its stake in Fennec Pharmaceuticals by 65.0% during the 2nd quarter. Hartford Financial Management Inc. now owns 20,300 shares of the company’s stock worth $81,000 after acquiring an additional 8,000 shares during the period. Paloma Partners Management Co bought a new position in Fennec Pharmaceuticals during the 2nd quarter worth $218,000. Finally, United Services Automobile Association increased its stake in Fennec Pharmaceuticals by 32.1% during the 2nd quarter. United Services Automobile Association now owns 229,983 shares of the company’s stock worth $920,000 after acquiring an additional 55,933 shares during the period. Hedge funds and other institutional investors own 42.57% of the company’s stock.
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Story: Closed-End Mutual Funds (CEFs)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.